Test Price
2,800 AED✅ Home Collection Available
KIF11 Gene Microcephaly with or without Chorioretinopathy, Lymphedema, or Mental Retardation (MCLMR) Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
Executive Clinical Summary
This advanced genetic test employs high-coverage Next-Generation Sequencing (NGS) to detect pathogenic variants in the KIF11 gene associated with Microcephaly with or without Chorioretinopathy, Lymphedema, or Mental Retardation (MCLMR). The assay is performed in an ISO 15189 accredited facility, ensuring 99.9% diagnostic sensitivity. It is conducted under the oversight of Consultant Medical Genetics and pediatric specialists to meet the highest clinical and regulatory standards in the UAE.
- 99.9% Accuracy Diagnostic sensitivity via ISO 15189 accredited genetic testing facility.
- Premium Logistics VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance Post-test telephonic clinical guidance for result interpretation by qualified genetic counsellors.
- Insurance Direct billing verification via WhatsApp: +971 54 548 8731.
Test Overview & Methodology
This test analyses the entire coding region of the KIF11 gene using high‑coverage Next‑Generation Sequencing (NGS) to identify pathogenic variants causing MCLMR syndrome, characterised by microcephaly, chorioretinopathy, lymphedema, and intellectual disability. In the UAE, turnaround time is 3‑4 weeks, ensuring rapid clinical decision‑making. The assay confirms all detected variants by Sanger sequencing, delivering definitive results.
| Feature | Our Test | Closest Alternative |
|---|---|---|
| Precision | Full gene NGS with >30× coverage, variant confirmation by Sanger | Limited panel, may not cover all exons |
| Method | NGS (Next Generation Sequencing), ISO 15189 validated | Sanger sequencing (single‑exon only, slower) |
| Speed | 3‑4 weeks from sample receipt | 6‑8 weeks |
Physician Insight & Safety Protocols
“As a DHA‑licensed Consultant Medical Genetics, I emphasise that a positive KIF11 genetic result confirms the clinical diagnosis but must be correlated with detailed ophthalmologic, neurodevelopmental, and lymphological evaluations. This test empowers families with clarity, yet genetic counselling remains essential to understand recurrence risks and family planning. Please do not discontinue any prescribed medications or therapies without consulting your referring physician.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Reg. ID: 9294403
Medication Advisory
Do not discontinue any prescribed antiepileptic, cardiac, or anti‑oedema medication without direct instruction from your treating doctor.
Genetic testing does not alter your current treatment plan; it only informs long‑term management.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Individuals unable to provide informed consent; minors must have legal guardian consent in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Exclusion: Patients refusing mandatory pre‑test genetic counselling session with a certified genetic counsellor.
- ER Red Flag: If the patient (especially a child) exhibits acute neurological deterioration, new‑onset seizures, or sudden vision loss, seek emergency medical attention immediately. This test is not a substitute for urgent clinical assessment.
Patient FAQ & Clinical Guidance
1. What is the KIF11 NGS test and why is it recommended for my child?
This test sequences the entire KIF11 gene to detect mutations causing microcephaly with lymphedema and chorioretinopathy, providing a definitive genetic diagnosis in one comprehensive assay.
2. How is the sample collected and is it painful?
A small amount of blood (2‑3 mL) is drawn from a vein in the arm, or a painless finger‑prick dry blood spot on an FTA card is sufficient, performed by our paediatric phlebotomist at your home at no extra cost.
3. Will my insurance cover the cost of this genetic test?
Many UAE insurance plans cover diagnostic genetic testing for suspected congenital syndromes when pre‑authorised; our team verifies your coverage via WhatsApp before collection.
UAE Regulatory & Data Privacy Adherence
At DNA Labs UAE, we operate under the DHA Facility License No. 1143. All genetic data is processed in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent for genetic testing follows Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genetic data is encrypted, never shared without explicit authorisation, and retained only as long as legally required.
Clinical & Logistical Metadata
| Test Name | KIF11 Gene Sequencing (NGS) for MCLMR |
| Price (AED) | 2,800 |
| Turnaround Time | 3‑4 weeks from sample receipt |
| Sample Type / Matrix | Peripheral whole blood (2‑3 mL EDTA) or dry blood spot (FTA card) |
| Methodology Used | Next‑Generation Sequencing (NGS) with Sanger confirmation, ISO 15189 validated |
| ICD-10-CM Code | Q02 (Microcephaly) |
| LOINC Code | 81421-7 (KIF11 gene mutation analysis in blood) |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE (DNA Labs UAE) |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians